OCT 22, 2020 1:35 PM PDT

Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Principal Research Scientist, Ontario Institute for Cancer Research
    Biography
      Dr. Bayani is a Principal Research Scientist at the Ontario Institute for Cancer Research in the Department of Diagnostic Development. She obtained her PhD at the University of Toronto in the Department of Laboratory Medicine and Pathobiology. She has an extensive background in molecular pathology and molecular cytogenetics and now leads a number of the genomic translational research projects as part of the senior scientific team in Diagnostic Development. Her focus is on precision medicine approaches for prognostic and predictive biomarkers in early hormone receptor positive breast cancers and in early prostate cancer.

    Abstract

    Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additional relevant biomarkers to existing tests, but ensuring they are adequately validated and robust for translation into a clinical research setting. The Oncomine Comprehensive Assay v3 has been implemented for use in both translational and clinical research projects including the NCI MATCH trial and shown reproducible and robust results. The newest version of the Oncomine Comprehensive Assay, Oncomine Comprehensive Assay Plus extends the already demonstrated high quality of performance into a larger targeted panel encompassing additional relevant content. Moreover, the extension of the panel allows for the determination of mutational signatures such as Tumour Mutational Burden (TMB) and Microsatellite Instabililty (MSI). This presentation will review our current experience with the Oncomine Comprehensive Assay Plus in the profiling of solid tissues from both formalin fixed paraffin embedded and fresh frozen material for use in the translational research setting.

    Learning Objectives:
    1. Identifying key performance metrics for choosing the right assay for clinical research studies
    2. Understanding the importance of a fluid workflow for integrating new content for precision medicine studies


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    Loading Comments...
    Show Resources